BRL-50481 is a drug developed by GlaxoSmithKline which is the first compound that acts as a phosphodiesterase inhibitor selective for the PDE7 subtype. It has been shown to increase mineralisation activity in osteoblasts suggesting a potential role for PDE7 inhibitors in the treatment of osteoporosis.
This page contains content from the copyrighted Wikipedia article "BRL-50481"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
